Met Life Investment Management, LLC Point Biopharma Global Inc. Transaction History

Met Life Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Apr 29, 2024	BUY	$6.86 - $10.86 $318,228 - $503,784	46,389 New	46,389 $420,000
Q1 2023 May 09, 2024	BUY	$6.78 - $8.1 $314,517 - $375,750	46,389 New	46,389 $337 Million
Q4 2022 May 10, 2024	BUY	$5.72 - $9.78 $31,196 - $53,340	5,454 Added 13.32%	46,389 $338,000
Q4 2022 Mar 22, 2023	BUY	$5.72 - $9.78 $31,196 - $53,340	5,454 Added 13.32%	46,389 $338,000
Q4 2022 Feb 15, 2023	BUY	$5.72 - $9.78 $31,196 - $53,340	5,454 Added 13.32%	46,389 $338,000
Q3 2022 Jun 14, 2023	SELL	$7.24 - $10.31 $39,486 - $56,230	-5,454 Reduced 11.76%	40,935 $316,000
Q2 2022 May 10, 2024	BUY	$5.6 - $9.5 $229,236 - $388,882	40,935 New	40,935 $278,000
Q2 2022 Jun 20, 2023	SELL	$5.6 - $9.5 $30,542 - $51,813	-5,454 Reduced 11.76%	40,935 $278,000
Q2 2022 Mar 22, 2023	SELL	$5.6 - $9.5 $30,542 - $51,813	-5,454 Reduced 11.76%	40,935 $278,000
Q2 2022 Aug 11, 2022	BUY	$5.6 - $9.5 $229,236 - $388,882	40,935 New	40,935 $279,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.